{"id":"NCT00244842","sponsor":"Aurinia Pharmaceuticals Inc.","briefTitle":"Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis","officialTitle":"A Phase III, Randomized, Multicentre, Double-Blind, Placebo-Controlled Study of ISA247 in Plaque Psoriasis Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-12","primaryCompletion":"2005-10","completion":"2005-10","firstPosted":"2005-10-27","resultsPosted":"2023-03-27","lastUpdate":"2023-03-27"},"enrollment":451,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"voclosporin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo Comparator: 1","type":"PLACEBO_COMPARATOR"},{"label":"Voclosporin 0.2 mg/kg po BID","type":"ACTIVE_COMPARATOR"},{"label":"Voclosporin 0.3 mg/kg po BID","type":"ACTIVE_COMPARATOR"},{"label":"Voclosporin 0.4 mg/kg po BID","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine which dose of voclosporin is effective in the treatment of plaque psoriasis compared to placebo.","primaryOutcome":{"measure":"Proportion of Subjects Achieving a PASI-75 at 12 Weeks at Each of the 3 Dose Levels of Voclosporin.","timeFrame":"Twelve Weeks","effectByArm":[{"arm":"Placebo","deltaMin":4,"sd":null},{"arm":"Voclosporin 0.2","deltaMin":14,"sd":null},{"arm":"Voclosporin 0.3","deltaMin":26,"sd":null},{"arm":"Voclosporin 0.4","deltaMin":44,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":21},"locations":{"siteCount":31,"countries":["Canada"]},"refs":{"pmids":["15371668","14672749","11250240","18424323"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":115},"commonTop":["Nasopharyngitis","Headache","Upper respiratory tract infection","Hypertension","Arthralgia"]}}